药物开发阶段的杂质表征:分析方法和监管视角
1Veranova, Devens, MA, USA. sramamoorthy.pharma@gmail.com.
Pharmaceutical research
|March 3, 2026
概括
确保药品安全需要严格控制杂质,如有机,无机,残留溶剂和基因毒性物种. 本综述详细介绍了在药物开发过程中有效管理杂质的最佳实践,先进分析和新兴趋势.
科学领域:
- 制药化学 制药化学 制药化学
- 分析化学 分析化学
- 药物开发 药物开发
背景情况:
- 杂质是制药合成和制造过程中不可避免的副产品.
- 控制杂质对于药物的安全性,有效性和质量至关重要.
- 不同的杂质类型 (有机,无机,残留溶剂,基因毒性) 需要不同的分析方法.
研究的目的:
- 综合杂质分类,来源映射和控制策略的最佳实践.
- 将杂质控制与全球监管指南 (ICH Q3A/B,Q3C,Q3D,M7) 保持一致.
- 审查杂质的先进分析技术和生命周期管理.
主要方法:
- 文献审查综合最佳实践和监管调整.
- 对先进的结构阐明工具 (LC-MS/MS,HRMS,NMR) 的调查.
- 讨论相应的分析,压力测试和稳定性指示方法.
主要成果:
- 介绍了杂质分类,来源映射和控制策略的框架.
- 强调致变物杂质 (例如,尼托胺) 和更新的风险管理.
- 讨论了绿色分析化学,AI,PAT和RTRT等新兴趋势.
结论:
- 强大的杂质管理对于制药合规性和发展加速至关重要.
- 积极的杂质预防策略正在从反应性检测重新定义控制.
- 为科学家,监管机构和质量专业人员提供了可行的框架.
关键词:
根据ICH的指导方针.在 LCMS 中使用.在PAT/RTRTT上使用.绿色分析化学 绿色分析化学通过杂质分析,进行了杂质分析.致变种杂质 致变种杂质酸氨基酸的含量是多少稳定性指示方法 稳定性指示方法更多相关视频
相关概念视频
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
In Vitro Drug Release Testing: Overview, Development and Validation
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...


